Insufficient serum caspofungin levels in a paediatric patient on ECMO

Caspofungin, aechinocandin, is a relatively new lipophilic antifungal drug. Little is known concerning the pharmacokinetics of caspofungin in children. Extracorporeal membrane oxygenation (ECMO) allows prolonged cardiopulmonary support in patients with life-threatening respiratory or cardiac failure...

Full description

Saved in:
Bibliographic Details
Published inMedical mycology case reports Vol. 2; pp. 23 - 24
Main Authors Koch, Birgit C P, Wildschut, Enno D, Goede, Anna L de, Hoog, Matthijs de, Brüggemann, Roger J M
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier 01.01.2013
Subjects
Therapeutic drug monitoring
Candidiasis
Pneumonia
Pharmacokinetics
Aspergillosis
Online AccessGet full text

Cover

More Information
Summary:Caspofungin, aechinocandin, is a relatively new lipophilic antifungal drug. Little is known concerning the pharmacokinetics of caspofungin in children. Extracorporeal membrane oxygenation (ECMO) allows prolonged cardiopulmonary support in patients with life-threatening respiratory or cardiac failure. Pharmacokinetics may be altered by ECMO. We describe the case of a paediatric patient on ECMO with severe pneumonia and sepsis, who had subtherapeutic exposure of caspofungin despite normal to high dosages of caspofungin. Therapeutic drug monitoring is warranted.
ISSN:2211-7539
2211-7539
DOI:10.1016/j.mmcr.2012.12.006